WXIBF (WuXi Biologics (Cayman)) Other Financing: $ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WXIBF WuXi Biologics (Cayman) Inc WXIBF
94 GF Score
Price $6.01
GF Value $5.41
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Other Financing?

WuXi Biologics (Cayman) WXIBF -3.45% 94 Other Financing is $ Mil as of Jun. 2026. GuruFocus rates WXIBF with a GF Score™ of 94/100 and a GF Value™ of $5.41 (Modestly Overvalued). The stock has 6 warning signs investors should review.

WuXi Biologics (Cayman)'s Other Financing for the six months ended in Jun. 2026 was $ Mil.

WuXi Biologics (Cayman)'s Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was $ Mil.

WuXi Biologics (Cayman) Other Financing Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Other Financing Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.10 -35.96 -32.10 -50.06 -41.69

WuXi Biologics (Cayman) Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.57 -28.62 -13.94 -28.12 -
WXIBF
94GF Score
WuXi Biologics (Cayman) Inc WXIBF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $ Mil mean?
WuXi Biologics (Cayman) (WXIBF) has a Other Financing of $ Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Other Financing too high?
WuXi Biologics (Cayman)'s current Other Financing is $ Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Other Financing compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Other Financing of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Other Financing is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.41, compared to a current price of $6.01 — trading 11.1% above its estimated fair value. The current Other Financing is $ Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Other Financing is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued. The current stock price of $6.01 is trading 11.1% above its estimated GF Value™ of $5.41. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Overvalued.

Key valuation signals for WXIBF:

  • Other Financing: $ Mil
  • GF Value™: $5.41 vs. price of $6.01 (11.1% above fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics (Cayman) Inc. is a global contract research, development, and manufacturing organization (CRDMO) focused on biologics. Incorporated in 2014 as a spin-off from WuXi PharmaTech, it provides end-to-end services spanning drug discovery, cell line development, clinical and commercial manufacturing, and formulation of antibodies, bispecifics, antibody-drug conjugates, and other biologics. The company operates through integrated platforms including WuXiBody and its multiple "biologics foundry" manufacturing facilities across China, Ireland, Germany, and the United States. Its customers are pharmaceutical and biotechnology companies worldwide, ranging from startups to large multinationals. Revenue is generated primarily through fee-for-service contracts tied to project milestones and commercial manufacturing agreements, with a significant portion derived from North American and European clients. WuXi Biologics competes with other large biologics CDMOs such as Lonza, Samsung Biologics, and Fujifilm Diosynth.
94GF Score

Get the complete analysis for WXIBF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.01
Price
$5.41
GF Value